Validated by studies of more than 1,500 patients in 3 prospective randomized clinical trial cohorts
Clinically actionable information
that can impact her treatment plan*
May support the decision to stop endocrine therapy
May support decision to extend endocrine therapy and encourage tight adherence
See how BCI benefits patients throughout the treatment journeyBCI patient Scenarios
Click on the test report numbers to learn more
• 0 – 10
• Individualized risk of late recurrence*
*If ordered at time of diagnosis, test report also provides overall (0 – 10 year), early (0 - 5 year), and late (5 - 10 year) risk of recurrence
• Predictive of likelihood of benefit from extended endocrine therapy
• HIGH or LOW (binary result)
…BCI might be useful in the setting of late disease recurrence, because it might provide a much needed means of identifying patients who could be spared extended adjuvant endocrine therapy and its well characterised adverse side-effects.
– Sgroi et al, TransATAC study, Lancet Oncol, 20132
BCI provides a quantitative assessment of the likelihood of distant recurrence in patients diagnosed with ER+ node-negative breast cancer, and prediction of likelihood of benefit from extended (>5 year) endocrine therapy in patients who are recurrence-free after an initial 5 years of adjuvant endocrine therapy. Treatment decisions require correlation with all other clinical findings. This test was developed and its performance characteristics determined by Biotheranostics, Inc. lt has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. lt should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. Biotheranostics is certified under the Clinical Laboratory lmprovement Amendments of 1988 to perform high-complexity clinical laboratory testing.